z-logo
open-access-imgOpen Access
Long-term culture system for selective growth of human B-cell progenitors.
Author(s) -
David J. Rawlings,
Shirley G. Quan,
Roberta M. Kato,
Owen N. Witte
Publication year - 1995
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.92.5.1570
Subject(s) - cd19 , biology , progenitor cell , stromal cell , stem cell factor , b cell , cell culture , cd38 , lymphopoiesis , microbiology and biotechnology , stem cell , haematopoiesis , cord blood , cd34 , immunology , flow cytometry , antibody , cancer research , genetics
We describe a simple reproducible system for enrichment and long-term culture of human B-cell progenitors. Enriched CD34+ cord blood mononuclear cells are seeded onto a murine stromal cell line to establish a biphasic culture system. These cultures are characterized by transient growth of myeloid cells followed by outgrowth of cells highly enriched for early B-cell progenitors. Cultures consisting of > 90% early B-lineage cells [expressing CD10, CD19, CD38, and CD45 but lacking CD20, CD22, CD23, and surface IgM] are maintained for > 12 weeks without growth factor addition. Cells remain predominantly germ line at the immunoglobulin locus and express only low levels of cytoplasmic mu chain, terminal deoxynucleotidyltransferase, and recombination-activating gene 1 product. They are unresponsive to the pre-B-cell growth factors interleukin 7 or stem cell factor, or both, suggesting that growth support is provided by a cross-reactive murine stromal cell factor. Cultured B-cell progenitors are generated in large numbers ( > 10(8) cells from a typical cord blood specimen) suitable for use in biochemical analysis and gene-transfer studies. This system should be useful for study of normal and abnormal early human B-lymphopoiesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here